Clinical Trial Update: Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) [Phase 2]

View source ↗

Summary

An open-label extension of ALK-001 in Stargardt disease (TEASE) is a Phase 2 study evaluating tolerability and effects; the trial is currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• ALK-001

Snippet

Sponsor: Alkeus Pharmaceuticals, Inc. | Conditions: Stargardt Disease, Stargardt Macular Degeneration | Phase 2 | Status: ACTIVE_NOT_RECRUITING